-
Something wrong with this record ?
Cancer-Cell-Intrinsic cGAS Expression Mediates Tumor Immunogenicity
L. Schadt, C. Sparano, NA. Schweiger, K. Silina, V. Cecconi, G. Lucchiari, H. Yagita, E. Guggisberg, S. Saba, Z. Nascakova, W. Barchet, M. van den Broek,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Cell Press Free Archives
from 2012
Directory of Open Access Journals
from 2012
Free Medical Journals
from 2012
Freely Accessible Science Journals
from 2012-01-26
Open Access Digital Library
from 2012-01-01
Open Access Digital Library
from 2012-01-26
- MeSH
- CD8-Positive T-Lymphocytes immunology MeSH
- Dendritic Cells metabolism MeSH
- Immunotherapy MeSH
- Interferon Type I metabolism MeSH
- Humans MeSH
- Membrane Proteins MeSH
- Microsatellite Repeats genetics MeSH
- Mice, Inbred C57BL MeSH
- Cell Line, Tumor MeSH
- Neoplasms drug therapy immunology pathology MeSH
- Nucleotides, Cyclic metabolism MeSH
- Nucleotidyltransferases metabolism MeSH
- DNA Damage MeSH
- Disease Progression MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Sensing of cytoplasmic DNA by cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) synthase (cGAS) results in production of the dinucleotide cGAMP and consecutive activation of stimulator of interferon genes (STING) followed by production of type I interferon (IFN). Although cancer cells contain supra-normal concentrations of cytoplasmic DNA, they rarely produce type I IFN spontaneously. This suggests that defects in the DNA-sensing pathway may serve as an immune escape mechanism. We find that cancer cells produce cGAMP that is transferred via gap junctions to tumor-associated dendritic cells (DCs) and macrophages, which respond by producing type I IFN in situ. Cancer-cell-intrinsic expression of cGAS, but not STING, promotes infiltration by effector CD8+ T cells and consequently results in prolonged survival. Furthermore, cGAS-expressing cancers respond better to genotoxic treatments and immunotherapy. Thus, cancer-cell-derived cGAMP is crucial to protective anti-tumor CD8+ T cell immunity. Consequently, cancer-cell-intrinsic expression of cGAS determines tumor immunogenicity and makes tumors hot. These findings are relevant for genotoxic and immune therapies for cancer.
Department of Immunology Juntendo University School of Medicine Tokyo 113 8421 Japan
Institute of Molecular Genetics of the ASCR v v i Videnska 1083 142 20 Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20025565
- 003
- CZ-PrNML
- 005
- 20201222155251.0
- 007
- ta
- 008
- 201125s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.celrep.2019.09.065 $2 doi
- 035 __
- $a (PubMed)31665636
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Schadt, Linda $u Institute of Experimental Immunology, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland.
- 245 10
- $a Cancer-Cell-Intrinsic cGAS Expression Mediates Tumor Immunogenicity / $c L. Schadt, C. Sparano, NA. Schweiger, K. Silina, V. Cecconi, G. Lucchiari, H. Yagita, E. Guggisberg, S. Saba, Z. Nascakova, W. Barchet, M. van den Broek,
- 520 9_
- $a Sensing of cytoplasmic DNA by cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) synthase (cGAS) results in production of the dinucleotide cGAMP and consecutive activation of stimulator of interferon genes (STING) followed by production of type I interferon (IFN). Although cancer cells contain supra-normal concentrations of cytoplasmic DNA, they rarely produce type I IFN spontaneously. This suggests that defects in the DNA-sensing pathway may serve as an immune escape mechanism. We find that cancer cells produce cGAMP that is transferred via gap junctions to tumor-associated dendritic cells (DCs) and macrophages, which respond by producing type I IFN in situ. Cancer-cell-intrinsic expression of cGAS, but not STING, promotes infiltration by effector CD8+ T cells and consequently results in prolonged survival. Furthermore, cGAS-expressing cancers respond better to genotoxic treatments and immunotherapy. Thus, cancer-cell-derived cGAMP is crucial to protective anti-tumor CD8+ T cell immunity. Consequently, cancer-cell-intrinsic expression of cGAS determines tumor immunogenicity and makes tumors hot. These findings are relevant for genotoxic and immune therapies for cancer.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a CD8-pozitivní T-lymfocyty $x imunologie $7 D018414
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a poškození DNA $7 D004249
- 650 _2
- $a dendritické buňky $x metabolismus $7 D003713
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunoterapie $7 D007167
- 650 _2
- $a interferon typ I $x metabolismus $7 D007370
- 650 _2
- $a membránové proteiny $7 D008565
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a mikrosatelitní repetice $x genetika $7 D018895
- 650 _2
- $a nádory $x farmakoterapie $x imunologie $x patologie $7 D009369
- 650 _2
- $a nukleotidy cyklické $x metabolismus $7 D009712
- 650 _2
- $a nukleotidyltransferasy $x metabolismus $7 D009713
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Sparano, Colin $u Institute of Experimental Immunology, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland.
- 700 1_
- $a Schweiger, Nicole Angelika $u Institute of Experimental Immunology, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland.
- 700 1_
- $a Silina, Karina $u Institute of Experimental Immunology, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland.
- 700 1_
- $a Cecconi, Virginia $u Institute of Experimental Immunology, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland.
- 700 1_
- $a Lucchiari, Giulia $u Institute of Experimental Immunology, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland.
- 700 1_
- $a Yagita, Hideo $u Department of Immunology, Juntendo University School of Medicine, Tokyo 113-8421, Japan.
- 700 1_
- $a Guggisberg, Emilien $u Institute of Experimental Immunology, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland.
- 700 1_
- $a Saba, Sascha $u Institute of Experimental Immunology, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland.
- 700 1_
- $a Nascakova, Zuzana $u Institute of Molecular Genetics of the ASCR, v. v. i., Videnska 1083, 142 20 Prague, Czech Republic.
- 700 1_
- $a Barchet, Winfried $u Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital and University of Bonn, Sigmund-Freud-Strasse 25, 35127 Bonn, Germany.
- 700 1_
- $a van den Broek, Maries $u Institute of Experimental Immunology, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland. Electronic address: vandenbroek@immunology.uzh.ch.
- 773 0_
- $w MED00188029 $t Cell reports $x 2211-1247 $g Roč. 29, č. 5 (2019), s. 1236-1248.e7
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31665636 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222155247 $b ABA008
- 999 __
- $a ok $b bmc $g 1599710 $s 1116251
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 29 $c 5 $d 1236-1248.e7 $e 20191029 $i 2211-1247 $m Cell reports $n Cell Rep $x MED00188029
- LZP __
- $a Pubmed-20201125